Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Rahima Zennadi
 -- 3228 2023-03-22 19:09:47 |
2 format change
Peter Tang
 Meta information modification 3228 2023-03-23 02:36:43 |

Video Upload Options

We provide professional Video Production Services to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Chauhan, W.; Zennadi, R. Keap1-Nrf2 Heterodimer in Sickle Cell Disease. Encyclopedia. Available online: https://encyclopedia.pub/entry/42446 (accessed on 19 November 2024).
Chauhan W, Zennadi R. Keap1-Nrf2 Heterodimer in Sickle Cell Disease. Encyclopedia. Available at: https://encyclopedia.pub/entry/42446. Accessed November 19, 2024.
Chauhan, Waseem, Rahima Zennadi. "Keap1-Nrf2 Heterodimer in Sickle Cell Disease" Encyclopedia, https://encyclopedia.pub/entry/42446 (accessed November 19, 2024).
Chauhan, W., & Zennadi, R. (2023, March 22). Keap1-Nrf2 Heterodimer in Sickle Cell Disease. In Encyclopedia. https://encyclopedia.pub/entry/42446
Chauhan, Waseem and Rahima Zennadi. "Keap1-Nrf2 Heterodimer in Sickle Cell Disease." Encyclopedia. Web. 22 March, 2023.
Keap1-Nrf2 Heterodimer in Sickle Cell Disease
Edit
This entry is adapted from the peer-reviewed paper 10.3390/antiox12030740

Sickle cell disease (SCD) is a monogenic inheritable disease characterized by severe anemia, increased hemolysis, and recurrent, painful vaso-occlusive crises due to the polymerization of hemoglobin S (HbS)-generated oxidative stress. Only four drugs are approved for SCD in the US. However, each of these drugs affects only a limited array of SCD pathologies. Importantly, curative therapies, such as gene therapy, or hematopoietic stem cell transplantation are not available for every patient because of their high costs, availability of donor matching, and their serious adverse effects. Therefore, there is an unmet medical need for novel therapeutic strategies that target broader SCD sequelae. SCD phenotypic severity can be alleviated by increasing fetal hemoglobin (HbF) expression. This results in the inhibition of HbS polymerization and thus sickling, and a reduction in oxidative stress. The efficacy of HbF is due to its ability to dilute HbS levels below the threshold required for polymerization and to influence HbS polymer stability in RBCs. Nuclear factor-E2-related factor 2 (Nrf2)/Kelch-like ECH-associated protein-1 (Keap1)-complex signaling is one of the most important cytoprotective signaling controlling oxidative stress. Nrf2 is present in most organs and, after dissociation from Keap1, it accumulates in the cytoplasm, then translocates to the nucleus where it binds to the antioxidant response element (ARE) sequences and increases the expression of various cytoprotective antioxidant genes. Keeping this in mind, various researchers have proposed a role of multiple agents, more importantly tert-Butylhydroquinone (tBHQ), curcumin, etc., (having electrophilic properties) in inhibiting keap1 activity, so that Nrf2 can translocate to the nucleus to activate the gamma globin gene, thus maintaining alpha-hemoglobin-stabilizing protein (AHSP) and HbF levels. This leads to reduced oxidative stress, consequently minimizing SCD-associated complications. 

sickle cell disease Nrf2-Keap1 signaling gamma globin oxidative stress antioxidant response element ROS therapeutic drugs cytoprotection

1. Introduction

Sickle cell disease (SCD) and β-thalassemia are the two major β-globin-associated recessively inherited hemoglobinopathies in which mutation in the β-globin gene causes reduced synthesis or improper functioning of hemoglobin due to an imbalance between the α- and β-chain [1]. In SCD, a single base is changed from adenine (A) to thymine (T) in the β-globin gene which leads to the replacement of glutamate by valine at the sixth position in the β-globin chain and the production of sickle hemoglobin (HbS). HbS has a lesser binding affinity towards oxygen than HbA (normal Hb); this reduced oxygen affinity causes polymerization of HbS, declining a greater oxygen binding affinity. Irrespective of oxygen partial pressure, the reduced affinity of HbS towards oxygen increases the tense conformation or T state during which hemoglobin is deoxygenated; a state furthering polymerization of HbS, which causes sickling of RBCs [2]. In SCD, oxidative stress is due to cyclic polymerization/depolymerization of HbS. Various reports have suggested that in SCD, the balanced redox reaction is disturbed due to catalysis of the Fenton reaction by the free hemoglobin released as a result of intravascular hemolysis, the recurrent ischemia-reperfusion injury promoting activation of the xanthine-xanthine oxidase system, and higher autoxidation of HbS generating reactive oxygen species (ROS) [3][4]. Protein phosphorylation, the activation of various transcription factors, apoptosis, immunity, and cell differentiation are all processes that depend on the proper generation and presence of ROS inside the cell, which must be controlled at low levels. As ROS production rises, it negatively impacts crucial cellular components such as proteins, lipids, and nucleic acids, ensuing oxidative stress [5][6].

2. Oxidative Stress in SCD

SCD is a complicated pathophysiologic disorder caused in part by several pro-oxidant mechanisms, resulting in chronic and systemic oxidative stress. Erythrocytes are continuously exposed to a free radical environment in healthy biological systems [7]. However, potential indicators of the severity of SCD include increased ROS generation and the byproducts of their oxidative reactions [8]. In SCD patients, the main source of pro-oxidants is the sickle erythrocyte, where unstable autoxidative HbS and higher metabolic turnover due to recurrent HbS polymerization and depolymerization produce enhanced ROS formation. In addition, sickle RBCs are subjected to continuous exogenous oxidative onslaughts, contributing to the evolution of SCD vasculopathy. Notably, nicotinamide adenine dinucleotide phosphate oxidases (NADPH oxidases), reported in sickle RBCs, may act as an incubator for oxidized Hb redox forms [9][10][11]. Further, ROS accumulation damages key sickle cell components. Increased ROS generation in sickle RBCs could contribute to cell membrane damage and premature hemolysis [12], and trigger sickle cell adhesion [10][13], consequently leading to severe anemia, vaso-occlusion, increased susceptibility to infections, chronic inflammatory diseases, and microvascular damage in organs [14]. These multifactorial events create a cyclic cascade, resulting in higher levels of ROS and oxidative damage, lower quality of life and life expectancy [15][16]. Many investigations have found that sickle erythrocytes produce twice as many superoxide (O2•−), hydrogen peroxide (H2O2), hydroxyl radical (HO•), and lipid oxidation products as HbA-containing erythrocytes [17]. The two primary antioxidant enzymes, glutathione peroxidase (GPx) and catalase (CAT), remove H2O2 that is generated either by a two-electron transfer or because of sickling. CAT is usually more significant than GPx because it can convert H2O2 into H2O, without burning cellular-reducing equivalents (glutathione (GSH) or nicotinamide adenine dinucleotide phosphate (NADPH)), which is a more energy-efficient way of eliminating H2O2. Interestingly, in transgenic sickle mouse models and SCD patients, certain investigations have found reduced CAT activity, but some contradicting reports have indicated instead increased CAT activity in SCD patients [16][18]. However, an increase in CAT activity may represent a defensive mechanism to scavenge H2O2 [16][18]. Yet, others have found that the activity of CAT in human sickle RBCs is not affected [19]. In disorders such as SCD where vascular oxidative stress is ensued by accumulations of ROS (superoxide anion, hydrogen peroxide, and the hydroxyl radical), vascular oxidative damage has long been linked to exposure to phosphatidylserine on RBCs [16]. Furthermore, in SCD patients, the normal antioxidant capacity of the RBC is impaired due to defects in the availability of antioxidants—lower levels of GSH, and enzymatic antioxidants such as peroxiredoxin 2 and non-enzymatic antioxidants such as vitamins C and E [19]. These findings, when considered collectively, point to oxidative stress playing a significant role in the pathophysiology of SCD [7][16][20].

3. Nrf2 Is a Basic Leucine Zipper Transcription Factor That Belongs to the Cap’n’collar Subfamily

Nrf2 is a cap’n’collar (CNC) transcription factor family member, including the founding member NF-E2p45. The transcription factor NF-E2p45 was initially discovered to bind to the erythroid gene regulatory element NF-E2 that is situated in the promoter region of the heme biosynthetic porphobilinogen deaminase gene (PBGD) [21]. Additionally, it was discovered that the transcription factor Nrf2 from humans binds to the gamma-globin gene regulatory region [22]. Along with NF-E2p45, the CNC family also consists of Nrf1, Nrf2, Nrf3, Bach1 (tBTB domain and CNC homolog 1), and Bach2. In contrast to the other proteins in the CNC family, Bach1 and Bach2 act as transcriptional repressors [21]. The basic leucine zipper (bZip) transcription factor is translocated to the nucleus and forms heterodimers with small musculoaponeurotic fibrosarcoma proteins (sMaf) K, G, and F [23]. This heterodimer then recognizes the antioxidant response element (an enhancer sequence) that is present in the regulatory regions of over 250 genes also known as AU-rich elements (AREs) [24]. There are 589 amino acids in Nrf2, containing seven Neh1-7 (N-terminal Nrf2-ECH homology) evolutionarily highly conserved domains. The Neh1 domain is a basic leucine zipper (bZip) motif. This motif recognizes DNA and facilitates its binding, and it is critical for Nrf2 dimerization with sMaf proteins [23]. The Neh2 domain has the ETGE motif located in the hydrophilic loop of the β-loop-β-structure at the C-terminal region and has a strong affinity for the β-propeller of Keap1-DC domain [25]. Similarly, the conserved DLG motif of Neh2 is located in a flexible region upstream of the core β-helix, and also binds Keap1-DC; however, with a noticeably reduced affinity [26]. Neh6, a serine-rich region containing the DSGIS and DSAPGS motifs, works as a degron to mediate Nrf2’s nuclear degradation [27]. The transactivation domains for Nrf2 include Neh4 and Neh5 and serve as the site for HRD1 binding [26][28]. These two domains regulate coordinately the transactivation of different cytoprotective genes [29]. Another domain, Neh7 (209-316 amino acid), was also found in Nrf2 which serves as a binding site for retinoid X receptor α (RXRα). The direct binding of RXRα to this domain inhibits the functions of Nrf2, and thereby inhibits expression of Nrf2 target genes [30][31].

4. Regulation of Nrf2

Regulation of NRF2 expression is mediated via three signaling pathways involving Keap1 (Kelch-like ECH-associated protein 1), HRD1, an E3 ubiquitin ligase involved in protein degradation [32], and E3 ligase adapter β-TrCP (β-transducin repeat-containing protein). These three proteins facilitate NRF2 proteasomal degradation by different mechanisms. As discussed above, Nrf2 has seven highly conserved domains (Neh1–Neh7) that make interactions possible with various different proteins, especially Keap1 [30]. The hydrophilic area of lysine residues (7K) in Neh2 is essential for Keap1-dependent polyubiquitination and Nrf2 degradation, and it also contains the ETGE and DLG motifs that are necessary for the interaction with Keap1 [26][33], whereas, the Keap1 has five domains and 624 amino acid residues. The intervening region (IVR) lies between the BTB and the Kelch domain, two protein–protein interaction motifs. The BTB domain and IVR’s N-terminal region work together to homodimerize Keap1 and connect to Cullin3 (Cul3) [34]. Cul3 is the core protein of the E3 ubiquitin–protein ligase complex, which facilitates target protein ubiquitination and proteasomal breakdown [34]. The interaction with Neh2 is mediated by the C-terminal region and the Kelch domain. With 27 cysteines in human protein, Keap1 has a high concentration of cysteine residues [35][36][37][38]. According to the “hinge and latch” model, the dimer of two keap1 molecules interacts with Nrf2 [39]. Thus, under basal conditions, the Nrf2 protein is tightly controlled by the Keap1–Cul3–E3 ubiquitin ligase complex to keep Nrf2 at its low level. Moreover, another recent research has revealed that the deubiquitinating enzyme USP15 also plays a significant part in controlling the ubiquitination and degradation of Nrf2 [40]. Keap1 is deubiquitinated by USP15, which also stabilizes and improves the E3 ligase activity of the Keap1–Cul3–E3 complex [34][40]. As a result, Nrf2 is eventually degraded. However, under induced conditions or oxidative stress, the controlling activity of the Keap1–Cul3–E3 ubiquitin ligase complex is impaired, and Nrf2 level increased [40]. Keap1 has been hypothesized to release Nrf2 by covalent modifications of the crucial cysteine residues (Cys-151, Cys-273, and Cys-288), since it is a thiol-rich protein and is therefore sensitive to an electrophile [41]. In other words, post-translational modifications in cysteine residues lead to the dissociation of the Cul3-based E3 ligase complex from Keap1. This dissociation helps prevent the proteasomal degradation of Nrf2 and leads to Nrf2 stabilization [42]. After dissociation, Nrf2 accumulates in the cytosol, then translocate to the nucleus, although the de novo generated Nrf2 was also found to accumulate in the cytoplasm and migrate into the nucleus rather than detaching from Keap1 [43]. In the nucleus, sMaf binds to Nrf2 and forms a heterodimerized form that can recognize and bind to the ARE sequences of various antioxidant enzymes (such as NAD(P)H quinone oxidoreductase 1 (NQO1), glutathione S-transferases (GST), superoxide dismutase (SOD), and heme oxygenase 1 (HO-1), etc.) and promote their expression to cope with oxidative stress [44].

5. The Molecular Activation and Cytoprotective Activity of the Keap1-Nrf2 Pathway against Oxidative Stress

Whenever cells encounter an unbalanced redox reaction or high levels of ROS, these cells acquire cytoprotection by activating the Keap1-Nrf2 pathway. This pathway consists of four interlinked constituents: inducers, Keap1 protein (senses the inducers), Nrf2, and target genes that execute the cytoprotection against oxidative stress. Under basal conditions, Keap1 binds to the ETGE and DLG motifs on Nrf2 and brings Nrf2 into the Keap1–Cul3–E3 ubiquitin ligase complex. Subsequently, Nrf2 is being degraded by the Keap1-dependent Cul3–E3 ubiquitin–proteasome pathway [45][46][47]. A cysteine code hypothesis is given, which states that in response to oxidative stress, these 27 cysteines are prime choices for electrophiles and oxidizing agents, because some of them are situated close to basic residues [48]. The functional significance of Cys151, Cys273, and Cys288 has been demonstrated by the fact that Cys151 is necessary for the inducer-induced activation of Nrf2, and that Cys273 and Cys288 are required for its repression [49]. Additionally, Cys226, Cys613, Cys622, and Cys624 residues have recently been found to be important for sensing hydrogen peroxide by forming the disulfide bond in order to maintain the fail-safe mechanism [47]. Although the pattern of modification of these cysteine residues by electrophiles is known as the “cysteine code” [50], the modification of cysteine residues causes conformational changes in the Keap1 that results in the disruption of Nrf2 from Keap1, and therefore inhibits the polyubiquitination of Nrf2 [35][36][38]. Thus, the stabilization of Nrf2 increases its nuclear localization and accumulation. In the nucleus, Nrf2 is heterodimerized with sMaf and then this heterodimerized Nrf2–sMaf complex recognizes the ARE sequences of various antioxidant genes and activates gene transcription [51]. Nrf2, in addition, competes with the transcription factor Bach1 for binding in the ARE motifs of antioxidant genes to regulate cellular oxidative stress levels [52][53].

6. Nrf2-Mediated Globin Gene Regulation

SCD phenotypic severity can be alleviated by increasing HbF expression to inhibit and thus reduce oxidative stress [54][55][56]. Most studies that propose to develop new SCD therapies aim to reactivate fetal γ-globin expression as their goal [57][58]. Infants with Hb SS have a delay in the fetal γ- to β-globin switch, and HbF levels average 9% at 24 months of age. This observation provided the impetus for widespread research efforts to understand the mechanisms of γ-globin gene regulation to develop strategies to reverse this process in SCD. The efficacy of HbF is due to its ability to dilute HbS levels below the threshold required for polymerization and to influence HbS polymer stability in the sickle RBCs [59]. To increase HbF expression, some research teams have tried to investigate how Nrf2 affects the regulation of the globin genes, particularly gamma globin, although there has not been much research carried out in this area up to now [60][61][62]. The β-locus control region (β-LCR), which has several Dnase1 hypersensitive sites, tightly controls the expression of the globin gene [63]. By interacting with transcription factors that connect these DNA regions to the RNA polymerase machinery, all of these sites are able to exert stimulatory, inhibitory, or more complex activities [64]. Hypersensitive site 2, which has tandem repeats present in the locus control region, helps with the expression of genes present in the globin gene cluster (add reference). These tandem repeats act as binding sites for activating protein 1 (AP1), nuclear factor erythroid 2, and Nrf2 (NF-E2-related factor 2) [22]. A strong acidic activation domain present in Nrf2 may contribute in the transcriptional stimulation of β-globin genes [22], although this function of Nrf2 is still unclear. Therefore, to evaluate the role of Nrf2 in the expression of the globin gene cluster, the human β-globin locus yeast artificial chromosome transgenic/NRF2 knockout (β-YAC/NRF2) mouse model was developed by a research team [65]. NRF2 loss decreased β-globin gene expression during erythropoiesis and eliminated dimethyl fumarate’s ability to increase β-globin transcription [62][66]. In β-YAC/NRF2 mice, it was found that the chromatin marks H3K4Me1 and H3K4Me3 were reduced, and that TATA-binding protein and RNA polymerase II were associated with the promoters of the globin and locus control region (LCR) genes [65].

7. Regulatory Role of Keap1-Nrf2 Heterodimer in Iron, Heme, and Hemoglobin Metabolism

Nrf2 mediates the cytoprotective response against oxidative stress by also influencing the iron-regulatory mechanism. For hemoglobin synthesis, iron is reutilized for RBC production in the spleen, while in an iron-overload condition, liver increases the production of a peptide hormone named hepcidin that maintains iron homeostasis [67]. Hepcidin degrades ferroportin (FPN1), the only iron exporter highly expressed in the basolateral membrane of the small intestine, and, thereby, decreases iron absorption in the small intestine [68][69]. Moreover, macrophages also scavenge heme and hemoglobin and degrade heme into biliverdin, free iron, and carbon monoxide through HO-1 activity [21][70]. This free iron can be stored with ferritin and exported by FPN1 to other cells for further utilization [21][70]. Ferritin is structurally a complex molecule of 24 heavy and light chains (FTH1 and LTH, respectively) in different ratios for various functions. Because FTH1 has oxidase activity, it stores the iron in a stable ferrihydrite form [21][71]. A study has found that the ARE, a 4 kb upstream transcription site in the FTH1 gene, is induced by Nrf2 and is responsible for the expression of FTH1 [71]. Additionally, the available literature suggests that AREs are also located 7 kb upstream of the FPN1 transcription start site and they are implicated in Nrf2-mediated regulation of the FPN1 gene [21][71]. Nrf2 signaling can be suppressed by Bach1, which forms a heterodimer by competing with Nrf2 in binding with the sMaf protein [53]. Heme, an inducer of HO-1, inactivates the Bach1 protein, promoting displacement of Bach1 from the sMaf-occupied HO-1 enhancers; a mechanism followed by Nrf2 binding to these elements [21][53].

8. Keap1–Nrf2 Signaling as a Potential Therapeutic Target in SCD

As per the paragraph, it is now clear that an enhanced expression of the gamma globin gene substantially ameliorates the complications of SCD. Additionally, the dissociation of Nrf2 from Keap1 substantially activates the expression of numbers of antioxidant enzymes in SCDs, and helps to maintain the balance between metabolic redox reactions [72]. Therefore, Keap1–Nrf2 signaling should also be considered as one of the plausible therapeutic target sites for the management of SCD. Here, there are some other approaches that have been found to be therapeutically significant to reduce the pathophysiology of SCD.
Aforesaid, activated Nrf2 further activates GSH and HO-1 along with various antioxidant enzymes [44]. Reduced GSH is tripeptide of L-glutamate, cysteine, and glycine synthesized by the reactions catalyzed by both gamma-glutamyl cysteine ligase and GSH synthetase in the cytosol [73][74]. GSH is actively oxidized by ROS and reduced to GSSG (glutathione disulfide), thus, providing cytoprotection [73][74]. It has been observed that GSH and glutamine levels are very much reduced in SCD, and supplementation of glutamine ameliorates the redox imbalance, pain crises, and other complications of the SCD [75][76]. Hence, it can be hypothesized that the Keap1-Nrf2 signaling pathway is potentially involved in regulating cellular GSH in SCD [77]. Similar results were observed when Keap1 was mutated or cells were under oxidative stress, showing that Nrf2 is active, but these cells were deficient in glutamine because of the increase in the activity of the cystine-glutamate antiporter protein xCT [78][79]. The xCT is encoded by SLC7A11, and activated by Nrf2, facilitating cystine entry into the cell [78][79]. The elevated level of xCT reduces the anaplerosis of the tricarboxylic acid (TCA) cycle and makes the cells dependent on glutamine catabolism to glutamate to support xCT flux [79]. That is why the supplementation of glutamine helps ameliorate SCD complications [75][80]. Similarly, Nrf2 encourages the usage of cysteine in the biosynthesis of the antioxidant GSH for the purpose of ROS detoxification [81][82]. Additionally, Nrf2 boosts the activity of gamma-glutamyl–cysteine ligase (GCL), a heterodimeric enzyme composed of both GCL catalytic subunit (GCLC) and GCL modifier subunit (GCLM), which catalyzes the first stage of GSH biosynthesis [82]. GCL makes it easier for cysteine and glutamate to combine and form gamma-glutamyl cysteine, which is a precursor to GSH [46][80][81][82]. Moreover, a group of scientists in 1997 observed the dynamic properties of S-nitrosohemoglobin in vasodilation control [83]. They have reported that the thiol groups presented in cysteine residues of beta-globin exhibit inhibitory effects of NO, due to the reaction between NO and reduced sulfhydryl groups (−SH) that generates S-nitrosothiols (RSNOs) [83][84]. Thiols such as GSH that possess a high affinity towards NO take part in trans-nitrosylation processes, where nitroso-Hb (SNO-Hb) transfers NO to the thiol to create nitrosoglutathione (GSNO) with good vasodilatory effects and leading to reduced pain crises in SCD [83].

References

  1. Schechter, A.N. Hemoglobin research and the origins of molecular medicine. Blood 2008, 112, 3927–3938.
  2. Kato, G.J.; Piel, F.B.; Reid, C.D.; Gaston, M.H.; Ohene-Frempong, K.; Krishnamurti, L.; Smith, W.R.; Panepinto, J.A.; Weatherall, D.J.; Costa, F.F.; et al. Sickle cell disease. Nat. Rev. Dis. Prim. 2018, 4, 18010.
  3. Chirico, E.N.; Pialoux, V. Role of oxidative stress in the pathogenesis of sickle cell disease. IUBMB Life 2012, 64, 72–80.
  4. Queiroz, R.F.; Lima, E.S. Oxidative stress in sickle cell disease. Rev. Bras. De Hematol. E Hemoter. 2013, 35, 16–17.
  5. Rajendran, P.; Nandakumar, N.; Rengarajan, T.; Palaniswami, R.; Gnanadhas, E.N.; Lakshminarasaiah, U.; Gopas, J.; Nishigaki, I. Antioxidants and human diseases. Clin. Chim. Acta 2014, 436, 332–347.
  6. Wu, J.Q.; Kosten, T.R.; Zhang, X.Y. Free radicals, antioxidant defense systems, and schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2013, 46, 200–206.
  7. Wang, Q.; Zennadi, R. The role of rbc oxidative stress in sickle cell disease: From the molecular basis to pathologic implications. Antioxidants 2021, 10, 1608.
  8. Nur, E.; Biemond, B.J.; Otten, H.-M.; Brandjes, D.P.; Schnog, J.-J.B.; CURAMA Study Group. Oxidative stress in sickle cell disease; pathophysiology and potential implications for disease management. Am. J. Hematol. 2011, 86, 484–489.
  9. George, A.; Pushkaran, S.; Konstantinidis, D.G.; Koochaki, S.; Malik, P.; Mohandas, N.; Zheng, Y.; Joiner, C.H.; Kalfa, T.A. Erythrocyte NADPH oxidase activity modulated by Rac GTPases, PKC, and plasma cytokines contributes to oxidative stress in sickle cell disease. Blood 2013, 121, 2099–2107.
  10. MacKinney, A.; Woska, E.; Spasojevic, I.; Batinic-Haberle, I.; Zennadi, R. Disrupting the vicious cycle created by NOX activation in sickle erythrocytes exposed to hypoxia/reoxygenation prevents adhesion and vasoocclusion. Redox Biol. 2019, 25, 101097.
  11. Alayash, A.I. Hemoglobin-based blood substitutes and the treatment of sickle cell disease: More harm than help? Biomolecules 2017, 7, 2.
  12. Kuypers, F.A.; Scott, M.D.; Schott, M.A.; Lubin, B.; Chiu, D.T. Use of ektacytometry to determine red cell susceptibility to oxidative stress. J. Lab. Clin. Med. 1990, 116, 535–545.
  13. Thamilarasan, M.; Estupinan, R.; Batinic-Haberle, I.; Zennadi, R. Mn porphyrins as a novel treatment targeting sickle cell NOXs to reverse and prevent acute vaso-occlusion in vivo. Blood Adv. 2020, 4, 2372–2386.
  14. Conran, N.; Belcher, J.D. Inflammation in sickle cell disease. Clin. Hemorheol. Microcirc. 2018, 68, 263–299.
  15. Barabino, G.A.; Platt, M.O.; Kaul, D.K. Sickle cell biomechanics. Annu. Rev. Biomed. Eng. 2010, 12, 345–367.
  16. Silva, D.G.H.; Belini Junior, E.; de Almeida, E.A.; Bonini-Domingos, C.R. Oxidative stress in sickle cell disease: An overview of erythrocyte redox metabolism and current antioxidant therapeutic strategies. Free. Radic. Biol. Med. 2013, 65, 1101–1109.
  17. Biswal, S.; Rizwan, H.; Pal, S.; Sabnam, S.; Parida, P.; Pal, A. Oxidative stress, antioxidant capacity, biomolecule damage, and inflammation symptoms of sickle cell disease in children. Hematology 2019, 24, 1–9.
  18. Pandey, K.B.; Rizvi, S.I. Biomarkers of oxidative stress in red blood cells. Biomed. Pap. 2011, 155, 131–136.
  19. Cho, C.-S.; Kato, G.J.; Yang, S.H.; Bae, S.W.; Lee, J.S.; Gladwin, M.T.; Rhee, S.G. Hydroxyurea-induced expression of glutathione peroxidase 1 in red blood cells of individuals with sickle cell anemia. Antioxid. Redox Signal. 2010, 13, 1–11.
  20. Hannemann, A.; Rees, D.C.; Brewin, J.N.; Noe, A.; Low, B.; Gibson, J.S. Oxidative stress and phosphatidylserine exposure in red cells from patients with sickle cell anaemia. British journal of haematology. Br. J. Haematol. 2018, 182, 567–578.
  21. Kasai, S.; Mimura, J.; Ozaki, T.; Itoh, K. Emerging regulatory role of Nrf2 in iron, heme, and hemoglobin metabolism in physiology and disease. Front. Vet. Sci. 2018, 5, 242.
  22. Moi, P.; Chan, K.; Asunis, I.; Cao, A.; Kan, Y.W. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc. Natl. Acad. Sci. USA 1994, 91, 9926–9930.
  23. Sengoku, T.; Shiina, M.; Suzuki, K.; Hamada, K.; Sato, K.; Uchiyama, A.; Kobayashi, S.; Oguni, A.; Itaya, H.; Kasahara, K.; et al. Structural basis of transcription regulation by CNC family transcription factor, Nrf2. Nucleic Acids Res. 2022, 50, 12543–12557.
  24. Cuadrado, A.; Manda, G.; Hassan, A.; Alcaraz, M.J.; Barbas, C.; Daiber, A.; Ghezzi, P.; León, R.; López, M.G.; Oliva, B.; et al. Transcription factor NRF2 as a therapeutic target for chronic diseases: A systems medicine approach. Pharm. Rev. 2018, 70, 348–383.
  25. Panda, H.; Wen, H.; Suzuki, M.; Yamamoto, M. Multifaceted Roles of the KEAP1–NRF2 System in Cancer and Inflammatory Disease Milieu. Antioxidants 2022, 11, 538.
  26. Tong, K.I.; Katoh, Y.; Kusunoki, H.; Itoh, K.; Tanaka, T.; Yamamoto, M. Keap1 recruits Neh2 through binding to ETGE and DLG motifs: Characterization of the two-site molecular recognition model. Mol. Cell. Biol. 2006, 26, 2887–2900.
  27. He, F.; Antonucci, L.; Karin, M. NRF2 as a regulator of cell metabolism and inflammation in cancer. Carcinogenesis 2020, 41, 405–416.
  28. Nam, L.B.; Keum, Y.-S. Binding partners of NRF2: Functions and regulatory mechanisms. Arch. Biochem. Biophys. 2019, 678, 108184.
  29. Zhang, J.; Hosoya, T.; Maruyama, A.; Nishikawa, K.; Maher, J.M.; Ohta, T.; Motohashi, H.; Fukamizu, A.; Shibahara, S.; Itoh, K.; et al. Nrf2 Neh5 domain is differentially utilized in the transactivation of cytoprotective genes. Biochem. J. 2007, 404, 459–466.
  30. Jaramillo, M.C.; Zhang, D.D. The emerging role of the Nrf2–Keap1 signaling pathway in cancer. Genes Dev. 2013, 27, 2179–2191.
  31. Wu, J.; Wang, H.; Tang, X. Rexinoid inhibits Nrf2-mediated transcription through retinoid X receptor alpha. Biochem. Biophys. Res. Commun. 2014, 452, 554–559.
  32. Kikkert, M.; Doolman, R.; Dai, M.; Avner, R.; Hassink, G.; van Voorden, S.; Thanedar, S.; Roitelman, J.; Chau, V.; Wiertz, E. Human HRD1 is an E3 ubiquitin ligase involved in degradation of proteins from the endoplasmic reticulum. J. Biol. Chem. 2004, 279, 3525–3534.
  33. Kobayashi, M.; Itoh, K.; Suzuki, T.; Osanai, H.; Nishikawa, K.; Katoh, Y.; Takagi, Y.; Yamamoto, M. Identification of the interactive interface and phylogenic conservation of the Nrf2-Keap1 system. Genes Cells 2002, 7, 807–820.
  34. Chauhan, N.; Chaunsali, L.; Deshmukh, P.; Padmanabhan, B. Analysis of dimerization of BTB-IVR domains of Keap1 and its interaction with Cul3, by molecular modeling. Bioinformation 2013, 9, 450–455.
  35. Kansanen, E.; Jyrkkänen, H.-K.; Levonen, A.-L. Activation of stress signaling pathways by electrophilic oxidized and nitrated lipids. Free Radic. Biol. Med. 2012, 52, 973–982.
  36. Kansanen, E.; Kuosmanen, S.M.; Leinonen, H.; Levonen, A.-L. The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer. Redox Biol. 2013, 1, 45–49.
  37. Scott, D.C.; Rhee, D.Y.; Duda, D.M.; Kelsall, I.R.; Olszewski, J.L.; Paulo, J.A.; de Jong, A.; Ovaa, H.; Alpi, A.F.; Harper, J.W.; et al. Two distinct types of E3 ligases work in unison to regulate substrate ubiquitylation. Cell 2016, 166, 1198–1214.e24.
  38. Taguchi, K.; Motohashi, H.; Yamamoto, M. Molecular mechanisms of the Keap1–Nrf2 pathway in stress response and cancer evolution. Genes Cells 2011, 16, 123–140.
  39. Tong, K.I.; Kobayashi, A.; Katsuoka, F.; Yamamoto, M. Two-site substrate recognition model for the Keap1-Nrf2 system: A hinge and latch mechanism. Biol. Chem. 2006, 387, 1311–1320.
  40. Villeneuve, N.F.; Tian, W.; Wu, T.; Sun, Z.; Lau, A.; Chapman, E.; Fang, D.; Zhang, D.D. USP15 negatively regulates Nrf2 through deubiquitination of Keap1. Mol. Cell 2013, 51, 68–79.
  41. McMahon, M.; Lamont, D.J.; Beattie, K.A.; Hayes, J.D. Keap1 perceives stress via three sensors for the endogenous signaling molecules nitric oxide, zinc, and alkenals. Proc. Natl. Acad. Sci. USA 2010, 107, 18838–18843.
  42. Suraweera, T.L.; Rupasinghe, H.P.V.; Dellaire, G.; Xu, Z. Regulation of Nrf2/ARE pathway by dietary flavonoids: A friend or foe for cancer management? Antioxidants 2020, 9, 973.
  43. Kobayashi, A.; Kang, M.-I.; Watai, Y.; Tong, K.I.; Shibata, T.; Uchida, K.; Yamamoto, M. Oxidative and electrophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1. Mol. Cell. Biol. 2006, 26, 221–229.
  44. Kaspar, J.W.; Niture, S.K.; Jaiswal, A.K. Nrf2: INrf2 (Keap1) signaling in oxidative stress. Free Radic. Biol. Med. 2009, 47, 1304–1309.
  45. McMahon, M.; Itoh, K.; Yamamoto, M.; Hayes, J.D. Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression. J. Biol. Chem. 2003, 278, 21592–21600.
  46. Sekhar, K.R.; Yan, X.X.; Freeman, M.L. Nrf2 degradation by the ubiquitin proteasome pathway is inhibited by KIAA0132, the human homolog to INrf2. Oncogene 2002, 21, 6829–6834.
  47. Suzuki, T.; Muramatsu, A.; Saito, R.; Iso, T.; Shibata, T.; Kuwata, K.; Kawaguchi, S.; Iwawaki, T.; Adachi, S.; Suda, H.; et al. Molecular mechanism of cellular oxidative stress sensing by Keap1. Cell Rep. 2019, 28, 746–758.e4.
  48. Dinkova-Kostova, A.T.; Holtzclaw, W.D.; Cole, R.N.; Itoh, K.; Wakabayashi, N.; Katoh, Y.; Yamamoto, M.; Talalay, P. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc. Natl. Acad. Sci. USA 2002, 99, 11908–11913.
  49. Saito, R.; Suzuki, T.; Hiramoto, K.; Asami, S.; Naganuma, E.; Suda, H.; Iso, T.; Yamamoto, H.; Morita, M.; Baird, L.; et al. Characterizations of three major cysteine sensors of Keap1 in stress response. Mol. Cell. Biol. 2016, 36, 271–284.
  50. Dinkova-Kostova, A.T.; Kostov, R.V.; Canning, P. Keap1, the cysteine-based mammalian intracellular sensor for electrophiles and oxidants. Arch. Biochem. Biophys. 2017, 617, 84–93.
  51. Ishii, T.; Itoh, K.; Takahashi, S.; Sato, H.; Yanagawa, T.; Katoh, Y.; Bannai, S.; Yamamoto, M. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J. Biol. Chem. 2000, 275, 16023–16029.
  52. Reichard, J.F.; Motz, G.T.; Puga, A. Heme oxygenase-1 induction by NRF2 requires inactivation of the transcriptional repressor BACH1. Nucleic Acids Res. 2007, 35, 7074–7086.
  53. Sun, J.; Brand, M.; Zenke, Y.; Tashiro, S.; Groudine, M.; Igarashi, K. Heme regulates the dynamic exchange of Bach1 and NF-E2-related factors in the Maf transcription factor network. Proc. Natl. Acad. Sci. USA 2004, 101, 1461–1466.
  54. Nur, E.; Brandjes, D.P.; Teerlink, T.; Otten, H.-M.; Oude Elferink, R.P.J.; Muskiet, F.; Evers, L.M.; ten Cate, H.; Biemond, B.J.; Duits, A.J.; et al. N-acetylcysteine reduces oxidative stress in sickle cell patients. Ann. Hematol. 2012, 91, 1097–1105.
  55. Lu, Z.H.; Steinberg, M.H. Fetal hemoglobin in sickle cell anemia: Relation to regulatory sequences cis to the β-globin gene. Blood 1996, 87, 1604–1611.
  56. Ley, T.J.; DeSimone, J.; Noguchi, C.T.; Turner, P.H.; Schechter, A.N.; Heller, P.; Nienhuis, A.W. 5-Azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia. Blood 1983, 62, 370–380.
  57. Shi, L.; Cui, S.; Engel, J.D.; Tanabe, O. Lysine-specific demethylase 1 is a therapeutic target for fetal hemoglobin induction. Nat. Med. 2013, 19, 291–294.
  58. Suzuki, M.; Yamamoto, M.; Engel, J.D. Fetal globin gene repressors as drug targets for molecular therapies to treat the β-globinopathies. Mol. Cell. Biol. 2014, 34, 3560–3569.
  59. Bookchin, R.M.; Nagel, R.L.; Balazs, T. Role of hybrid tetramer formation in gelation of haemoglobin S. Nature 1975, 256, 667–668.
  60. Macari, E.; West, R.; Lowrey, W.J.; Mabaera, R.; Lowrey, C.H. Induction of γ-Globin Gene Expression Via the Nrf2/Antioxidant Response Element Signaling Pathway. Blood 2009, 114, 975.
  61. Akino, N.; Wada-Hiraike, O.; Isono, W.; Terao, H.; Honjo, H.; Miyamoto, Y.; Tanikawa, M.; Sone, K.; Hirano, M.; Harada, M.; et al. Activation of Nrf2/Keap1 pathway by oral Dimethylfumarate administration alleviates oxidative stress and age-associated infertility might be delayed in the mouse ovary. Reprod. Biol. Endocrinol. 2019, 17, 23.
  62. Macari, E.R.; Lowrey, C.H. Induction of human fetal hemoglobin via the NRF2 antioxidant response signaling pathway. Blood 2011, 117, 5987–5997.
  63. Driscoll, M.C.; Dobkin, C.S.; Alter, B.P. Gamma delta beta-thalassemia due to a de novo mutation deleting the 5’beta-globin gene activation-region hypersensitive sites. Proc. Natl. Acad. Sci. USA 1989, 86, 7470–7474.
  64. Cao, A.; Moi, P. Regulation of the globin genes. Pediatr. Res. 2002, 51, 415–421.
  65. Zhu, X.; Xi, C.; Ward, A.; Takezaki, M.; Shi, H.; Peterson, K.R.; Pace, B.S. NRF2 mediates γ-globin gene regulation through epigenetic modifications in a β-YAC transgenic mouse model. Exp. Biol. Med. 2020, 245, 1308–1318.
  66. Macari, E.R.; Schaeffer, E.K.; West, R.J.; Lowrey, C.H. Simvastatin and t-butylhydroquinone suppress KLF1 and BCL11A gene expression and additively increase fetal hemoglobin in primary human erythroid cells. Blood 2013, 121, 830–839.
  67. Pagani, A.; Nai, A.; Silvestri, L.; Camaschella, C. Hepcidin and anemia: A tight relationship. Front. Physiol. 2019, 10, 1294.
  68. Chauhan, W.; Shoaib, S.; Fatma, R.; Zaka-ur-Rab, Z.; Afzal, M. Beta-thalassemia and the advent of new interventions beyond transfusion and iron chelation. Br. J. Clin. Pharmacol. 2022, 88, 3610–3626.
  69. Gulec, S.; Anderson, G.J.; Collins, J.F. Mechanistic and regulatory aspects of intestinal iron absorption. Am. J. Physiol.-Gastrointest. Liver Physiol. 2014, 307, G397–G409.
  70. Drakesmith, H.; Nemeth, E.; Ganz, T. Ironing out ferroportin. Cell Metab. 2015, 22, 777–787.
  71. Marro, S.; Chiabrando, D.; Messana, E.; Stolte, J.; Turco, E.; Tolosano, E.; Muckenthaler, M.U. Heme controls ferroportin1 (FPN1) transcription involving Bach1, Nrf2 and a MARE/ARE sequence motif at position− 7007 of the FPN1 promoter. Haematologica 2010, 95, 1261–1268.
  72. Wu, S.; Lu, H.; Bai, Y. Nrf2 in cancers: A double-edged sword. Cancer Med. 2019, 8, 2252–2267.
  73. Narayanankutty, A.; Job, J.T.; Narayanankutty, V. Glutathione, an antioxidant tripeptide: Dual roles in carcinogenesis and chemoprevention. Curr. Protein. Pept. Sci. 2019, 20, 907–917.
  74. Lu, S.C. Glutathione synthesis. Biochim. Biophys. Acta 2013, 1830, 3143–3153.
  75. Niihara, Y.; Miller, S.T.; Kanter, J.; Lanzkron, S.; Smith, W.R.; Hsu, L.L.; Gordeuk, V.R.; Viswanathan, K.; Sarnaik, S.; Osunkwo, I.; et al. A phase 3 trial of l-glutamine in sickle cell disease. N. Engl. J. Med. 2018, 379, 226–235.
  76. Morris, C.R.; Suh, J.H.; Hagar, W.; Larkin, S.; Bland, D.A.; Steinberg, M.H.; Vichinsky, E.P.; Shigenaga, M.; Ames, B.; Kuypers, F.A.; et al. Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. Blood 2008, 111, 402–410.
  77. Harvey, C.J.; Thimmulappa, R.K.; Singh, A.; Blake, D.J.; Ling, G.; Wakabayashi, N.; Fujii, J.; Myers, A.; Biswal, S. Nrf2-regulated glutathione recycling independent of biosynthesis is critical for cell survival during oxidative stress. Free Radic. Biol. Med. 2009, 46, 443–453.
  78. Romero, R.; Sayin, V.I.; Davidson, S.M.; Bauer, M.R.; Singh, S.X.; LeBoeuf, S.E.; Karakousi, T.R.; Ellis, D.C.; Bhutkar, A.; Sánchez-Rivera, F.J.; et al. Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. Nat. Med. 2017, 23, 1362–1368.
  79. Muir, A.; Danai, L.V.; Gui, D.Y.; Waingarten, C.Y.; Lewis, C.A.; Vander Heiden, M.G. Environmental cystine drives glutamine anaplerosis and sensitizes cancer cells to glutaminase inhibition. eLife 2017, 6, e27713.
  80. DeBlasi, J.M.; DeNicola, G.M. Dissecting the crosstalk between NRF2 signaling and metabolic processes in cancer. Cancers 2020, 12, 3023.
  81. Moinova, H.R.; Mulcahy, R.T. Up-regulation of the human γ-glutamylcysteine synthetase regulatory subunit gene involves binding of Nrf-2 to an electrophile responsive element. Biochem. Biophys. Res. Commun. 1999, 261, 661–668.
  82. Solis, W.A.; Dalton, T.P.; Dieter, M.Z.; Freshwater, S.; Harrer, J.M.; He, L.; Shertzer, H.G.; Nebert, D.W. Glutamate–cysteine ligase modifier subunit: Mouse Gclm gene structure and regulation by agents that cause oxidative stress. Biochem. Pharmacol. 2002, 63, 1739–1754.
  83. Jia, L.; Bonaventura, C.; Bonaventura, J.; Stamler, J.S. S-nitrosohaemoglobin: A dynamic activity of blood involved in vascular control. Nature 1996, 380, 221–226.
  84. Tejedor, C.; Lorente, J.A.; Delgado, M.A.; Fernández-Segoviano, P.; de Paula, M.; Tobalina, R.; Alonso, M.; Moscoso, A.; Soto, F.; Blázquez, J.; et al. Interaction between hemoglobin and glutathione in the regulation of blood flow in normal and septic pigs*. Crit. Care Med. 2002, 30, 2493.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Biology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Waseem Chauhan
,
Rahima Zennadi
View Times: 318
Revisions: 2 times (View History)
Update Date: 29 Mar 2023
Table of Contents
    1000/1000
    Hot Most Recent
    ScholarVision Creations
    Feedback